Louise M. Causer, M.B.B.S.1,2 Robert D. Newman, M.D.1,2 Ann M. Barber2
Jacquelin M. Roberts, M.S.2 Gail Stennies, M.D.2 Peter B. Bloland, D.V.M.2 Monica E. Parise, M.D.2 Richard W. Steketee, M.D.2
1Epidemic Intelligence Service
Epidemiology Program Office
2Division of Parasitic Diseases
National Center for Infectious Diseases
Abstract
Problem/Condition: Malaria is caused by four species of intraerythrocytic protozoa of the genus
Plasmodium (i.e., P. falciparum, P.
vivax, P. ovale, or P. malariae). Malaria is transmitted by the bite of an infective female
Anopheles sp. mosquito. The majority of malaria infections in the United States occur among persons who have traveled to
areas with ongoing transmission. In the United States, cases can occur through exposure to infected blood products,
by congenital transmission, or locally through mosquitoborne transmission. Malaria surveillance is conducted
to identify episodes of local transmission and to guide prevention recommendations for travelers.
Period Covered: Cases with onset of illness during 2000.
Description of System: Malaria cases confirmed by blood smear are reported to local and state health
departments by health-care providers or laboratory staff. Case investigations are conducted by local and state health
departments, and reports are transmitted to CDC through the National Malaria Surveillance System (NMSS). Data from
NMSS serve as the basis for this report.
Results: CDC received reports of 1,402 cases of malaria with an onset of symptoms during 2000 among persons
in the United States or one of its territories. This number represents a decrease of 9.0% from the 1,540 cases
reported for 1999. P. falciparum, P.
vivax, P. malariae, and P. ovale were identified in 43.6%, 37.2%, 4.8%, and 2.3% of
cases,
respectively. Nine patients (0.6% of total) were infected by
>2 species. The infecting species was unreported
or undetermined in 161 (11.5%) cases. Compared with 1999, the number of reported malaria cases acquired in
Africa decreased by 13.1% (n = 783), and a decrease of 3.3% (n = 238) occurred in cases acquired in Asia. Cases from
the Americas decreased by 1.1% (n = 271) from 1999. Of 825 U.S. civilians who acquired malaria abroad, 190
(23.0%) reported that they had followed a chemoprophylactic drug regimen recommended by CDC for the area to
which they had traveled. Four patients became infected in the United States, two through congenital transmission and
two through probable induced transmission. Six deaths were attributed to malaria, four caused by
P. falciparum, one caused by P.
malariae, and one by P. ovale.
Interpretation: The 9.0% decrease in malaria cases in 2000, compared with 1999, resulted primarily from
decreases in cases acquired in Africa and Asia. This decrease could have resulted from local changes in disease
transmission, decreased travel to these regions, fluctuation in reporting to state and local health departments, or an increased use
of effective antimalarial chemoprophylaxis. In the majority of reported cases, U.S. civilians who acquired
infection abroad were not on an appropriate chemoprophylaxis regimen for the country in which they acquired malaria.
Public Health Actions: Additional information was obtained concerning the six fatal cases and the four
infections acquired in the United States. Persons traveling to a malarious area should take one of the
recommended chemoprophylaxis regimens appropriate for the region of travel, and travelers should use personal
protection measures to prevent mosquito bites. Any person who has been to a malarious area and who subsequently develops
a fever or influenza-like symptoms should seek medical care immediately and report their travel history to
the clinician; investigation should include a blood-film test for malaria. Malaria infections can be fatal if not
diagnosed and treated promptly. Recommendations concerning malaria prevention can be obtained from CDC by calling
the Malaria Hotline at 770-488-7788 or by accessing CDC's Internet site at http://www.cdc.gov/travel.
Introduction
Malaria is caused by infection with one or more of four species of
Plasmodium (i.e., P. falciparum, P.
vivax, P. ovale, and P. malariae) that can infect humans. The infection is transmitted by the bite of an infective female
Anopheles sp. mosquito. Malaria infection remains a devastating global problem, with an estimated 300--500 million cases occurring annually
(1). Forty-one percent of the world's population lives in areas where malaria is transmitted (e.g., parts of Africa, Asia, the
Middle East, Central and South America, Hispaniola, and Oceania)
(1), and 700,000--2.7 million persons die of malaria each
year, 75% of them African children (2). In previous years, malaria was endemic throughout much of the continental United
States; an estimated 600,000 cases occurred during 1914
(3). During the late 1940s, a combination of improved
socioeconomic conditions, water management, vector-control efforts, and case management was successful at interrupting
malaria transmission in the United States. Since then, malaria case surveillance has been maintained to detect locally acquired
cases that could indicate the reintroduction of transmission and to monitor patterns of antimalarial drug resistance that
guide prevention recommendations for U.S. travelers. Anopheline mosquitos remain seasonally present in all states except Hawaii.
Through 2000, the majority of cases of malaria diagnosed in the United States have been imported from regions of the
world where malaria transmission is known to occur, although congenital infections and infections resulting from exposure to blood
or blood products are reported in the United States also. In addition, a limited number of cases are reported that might have
been acquired through local mosquitoborne transmission
(4).
State and local health departments and CDC investigate malaria cases acquired in the United States, and CDC
analyzes data from imported cases to detect acquisition trends. This information is used to guide malaria prevention
recommendations for travelers abroad. For example, an increase in
P. falciparum malaria among U.S. travelers to Africa, an area with
increasing chloroquine resistance, prompted CDC to change the recommended chemoprophylaxis regimen from chloroquine
to mefloquine in 1990 (5).
The signs and symptoms of malaria illness are varied, but the majority of patients experience fever. Other
common symptoms include headache, back pain, chills, increased sweating, myalgia, nausea, vomiting, diarrhea, and cough.
The diagnosis of malaria should be considered for persons who experience these symptoms and who have traveled to an area
with known malaria transmission. Malaria should also be considered in the differential diagnoses of persons who experience
fevers
of unknown origin, regardless of their travel history. Untreated
P. falciparum infections can rapidly progress
to coma, renal failure, pulmonary edema, and death. Asymptomatic parasitemia can occur among persons who have been long-term residents
of malarious areas. This report summarizes malaria cases reported to CDC with onset of symptoms in 2000.
Methods
Data Sources
Malaria case data are reported to the National Malaria Surveillance System (NMSS) and the National Notifiable
Diseases Surveillance System (NNDSS) (6). Although both systems rely on passive reporting, the numbers of reported cases
might differ between the two systems because of differences in collection and transmission of data. A major difference in the
data collected in these two systems is that NMSS receives more detailed clinical and epidemiologic data regarding each case
(e.g., information concerning the area to which the infected person has traveled). This report presents only data regarding
cases reported to NMSS.
Cases of blood-film--confirmed malaria among civilians and military personnel are identified by health-care providers
or laboratories. Each slide-confirmed case is reported to local or state health departments and to CDC on a uniform case
report form that contains clinical, laboratory, and epidemiologic information. CDC staff review all report forms when received
and request additional information, if necessary (e.g., when no recent travel to a malarious country is reported). Reports of
other cases are telephoned directly by health-care providers to CDC, usually when assistance with diagnosis or treatment
is requested. All cases that have been acquired in the United States are investigated, including all induced and congenital
cases and possible introduced or cryptic cases. Information derived from uniform case report forms is entered into a database
and analyzed annually.
Definitions
The following definitions are used in this report:
Laboratory criteria for diagnosis: Demonstration of malaria parasites in blood films.
Confirmed case: Symptomatic or asymptomatic infection that occurs in a person in the United States who
has microscopically confirmed malaria parasitemia, regardless of whether the person had previous episodes of malaria while
in other countries. A subsequent episode of malaria is counted as an additional case if the identified
Plasmodium sp. differs from the initially identified species. A subsequent episode of malaria occurring in a person while in the United
States could indicate a relapsing infection or treatment failure resulting from drug resistance if the identified
Plasmodium sp. is the same species identified previously.
This report also uses terminology derived from the recommendations of the World Health Organization;
(7). Definitions of the following terms are included for reference:
Autochthonous malaria:
Indigenous. Mosquitoborne transmission of malaria in a geographic area where malaria occurs regularly.
Introduced. Mosquitoborne transmission of malaria from an imported case in an area where malaria does not
occur regularly.
Imported malaria: Malaria acquired outside a specific area. In this report, imported cases are those acquired outside
the United States and its territories (Puerto Rico, Guam, and the U.S. Virgin Islands).
Induced malaria: Malaria acquired through artificial means (e.g., blood transfusion or using shared common syringes).
Relapsing malaria: Renewed manifestations (i.e., clinical symptoms or parasitemia) of malarial infection that is
separated from previous manifestations of the same infection by an interval greater than the usual periodicity of the paroxysms.
Cryptic malaria: An isolated malaria case that cannot be linked epidemiologically to secondary cases.
Microscopic Diagnosis of Malaria
The early diagnosis of malaria requires that physicians consider malaria in the differential diagnosis of every patient who
is experiencing fever; the evaluation of such a patient should include taking a comprehensive travel history. If malaria
is suspected, a Giemsa-stained smear of the patient's peripheral blood should be examined for parasites. Thick and thin
blood
films must be prepared correctly because diagnostic accuracy depends on blood-film quality and examination by
experienced laboratory personnel* (see Appendix for procedures for accurately diagnosing malaria).
Results
General Surveillance
During 2000, CDC received 1,402 malaria case reports
occurring among persons in the United States and its
territories, representing a 9.0% decrease from the 1,540 cases reported for 1999
(8). This incidence is the third highest number
of reported cases since 1980 and represents the second highest number of U.S. civilian cases reported in the past 30 years
(Table 1). In 2000, a total of 827 cases occurred among U.S. civilians, compared with 833 cases reported for 1999, and the
number of cases among foreign civilians also decreased from 381 cases to 354 (Figure 1). Cases among U.S. military
personnel decreased from 55 to 46 in 2000. In 175 cases, information was insufficient to determine civilian or military status.
Plasmodium Species
The infecting species of Plasmodium was identified in 1,241 (88.5%) of the cases reported in 2000.
P. falciparum and P. vivax were identified in blood smears from 43.6% and 37.2% of infected persons, respectively (Table 2). The
611 P. falciparum cases reported for 2000 represented a 13.7% decrease from the 708 cases in 1999, whereas the number of
P. vivax infections increased by 10.6% (from 472 in 1999 to 522 in 2000). Among 1,181 cases in which both the region
of acquisition and the infecting species were known, 75.6% of infections acquired in Africa were attributed to
P. falciparum; 13.2% were attributed to P.
vivax. The converse was true of infections acquired in the Americas and Asia: 86.5% and
85.9% were attributed to P. vivax, and only 7.3% and 8.3% were attributed to
P. falciparum, respectively.
Region of Acquisition and Diagnosis
Approximately 99% (n = 1,398) of reported cases were imported. Of 1,330 imported cases in which the region
of acquisition was known, the majority (58.9%; n = 783) were acquired in Africa; 20.1% (n = 271) and 17.9% (n = 238)
were acquired in the Americas and Asia, respectively
(Table 3). The highest concentration of cases acquired in Africa came
from countries in West Africa (66.7%; n = 522), whereas the majority of cases acquired in Asia came from the Indian
subcontinent (67.2%; n = 160). The other regions where imported cases of malaria were acquired were Central America and the
Caribbean (15.0%; n = 200), South America (4.3%; n = 57), and Oceania (1.7%; n = 22). Information regarding region of
acquisition was missing for 68 (4.9%) of the imported cases. The number of reported malaria cases acquired in Africa decreased
by 13.1% (n = 783), compared with 1999. The same number of cases acquired in the Americas (n = 271) were reported for
2000 as compared with 1999. Cases from Asia decreased by 3.3% (n = 238), compared with 1999.
In the United States, the five health departments reporting the highest number of malaria cases were New York City (n
= 220), California (n = 194), New York State (n = 77), Texas
(n = 70), and Illinois (n = 67) (Figure 2). All of these
health departments reported a decrease in cases compared with 1999. This overall decrease in reported number of cases might
reflect a decreased rate of international travel, a reduced risk
for malaria among travelers, poorer access to health care, or fluctuation
in surveillance by state and local health departments.
Interval Between Arrival and Illness
The interval between date of arrival in the United States and onset of illness and the infecting
Plasmodium species were known for 623 (44.6%) of the imported cases of malaria
(Table 4). Symptoms began before arrival in the United States for
63 (10.1%) persons, whereas symptoms began after arrival in the United States for 560 (89.9%) of these patients.
Clinical malaria developed within 1 month after arrival in 313 (80.9%) of the 387
P. falciparum cases and in 75 (38.9%) of the 193
P. vivax cases (Table 4). Only 5 (0.8%) of the 560 persons became ill >1 year after returning to the United States.
Imported Malaria Cases
Imported Malaria Among U.S. Military Personnel
In 2000, a total of 46 cases of imported malaria were reported among U.S. military personnel. Of the 45 cases for
whom information regarding chemoprophylaxis use was available, seven patients were not using any prophylaxis.
Imported Malaria Among Civilians
A total of 1,179 imported malaria cases were reported among civilians. Of these, 825 (70.0%) cases occurred among
U.S. residents, and 354 (30.0%) cases occurred among residents of other countries (Table 5). Of the 825 imported malaria
cases among U.S. civilians, 555 (67.3%) had been acquired in Africa, an increase of 1.1% from cases reported in 1999.
Asia accounted for 106 (12.8%) cases of imported malaria among U.S. civilians, whereas travel to the Central American
and Caribbean regions accounted for an additional 90 (10.9%) cases. Of the 354 imported cases among foreign civilians,
the majority of cases were acquired in either Africa (n = 150; 42.4%) or Asia (n = 90; 25.4%).
Antimalarial Chemoprophylaxis Use
Chemoprophylaxis Use Among U.S. Civilians
Information concerning chemoprophylaxis use and travel area was known for 758 (91.9%) of the 825 U.S. civilians
who had imported malaria. Of these 758 persons, 452 (59.6%) had not taken any chemoprophylaxis, and 94 (12.4%) had
not taken a CDC-recommended drug for the area visited
(9). Only 190 (25.1%) U.S. civilians had taken a
CDC-recommended medication (9). Data for the specific drug taken were missing for the remaining 22 (2.9%) travelers. A total of 128
(67.4%) patients on CDC-recommended prophylaxis had taken mefloquine weekly; 22 (11.6%) had taken doxycycline daily; and
21 (11.1%) who had traveled only in areas where chloroquine-resistant malaria has not been documented, had taken
chloroquine weekly. Nineteen patients (10.0%) had taken combinations of drugs that included
>1 CDC-recommended drugs for the travel region. Of the 94 patients taking a nonrecommended drug, 54 (57.4%) reported taking chloroquine either alone or
in combination with another ineffective drug during travel to an area where chloroquine resistance has been documented.
Malaria Infection After Recommended Prophylaxis Use
A total of 236 patients (i.e., 190 U.S. civilians, 32 persons in the U.S. military, 6 foreign civilians, and 8 persons
whose information regarding their status was missing) experienced malaria after taking a recommended antimalarial drug
for chemoprophylaxis. Information regarding infecting species was available for 209 (88.6%) patients taking a
recommended antimalarial drug; the infecting species was undetermined for the remaining 27.
Cases of P. vivax or P. ovale After Recommended Prophylaxis
Use. Of the 236 patients who experienced malaria
after recommended chemoprophylaxis use, 121 cases (51.3%) were caused by
P. vivax and 10 (4.2%) by P. ovale. Notes on
the malaria case surveillance reports indicated that 25 (19.1%) of these 131 patients were noncompliant with
antimalarial prophylaxis.
A total of 39 (29.8%) cases of P. vivax or
P. ovale occurred >45 days after arrival in the United States. These cases
were consistent with relapsing infections and, thus, do not indicate prophylaxis failures. Information was insufficient, because
of missing data regarding symptom onset or return date, to assess whether 77 cases were relapsing infections. Fifteen cases,
all caused by P. vivax, occurred
<45 days after the patient returned (n = 12) or before return (n = 3) to the United States. Of
these 15 patients, five were known to be noncompliant with their antimalarial chemoprophylaxis. Region of acquisition varied
for the 10 remaining case patients who were not known to be noncompliant (one from West Africa, one from East Africa,
one from Central Africa,† five from Central America, and two from Papua New Guinea). Blood samples were not
available; therefore, serum drug levels were not measured for any of these patients. The probable explanations for these cases are
either inappropriate dosing or noncompliance that was not reported. Evidence is lacking that would indicate any new area
of chloroquine-resistant P. vivax.
Cases of P. falciparum and P. malariae
After Recommended Prophylaxis Use. The remaining 105 cases of
malaria reported among persons who had taken a recommended antimalarial drug for chemoprophylaxis include 61 cases
of P. falciparum, 16 cases of P.
malariae, one case of mixed infection, and 27 cases in which the infecting species
was unidentified.
A total of 59 of the 61 P. falciparum cases among those who reported taking a recommended antimalarial drug
were acquired in Africa, one in the Caribbean, and one in South America. In 24 (39.3%) of these 61 cases, noncompliance
with antimalarials was reported. Of the remaining 37 cases of
P. falciparum for which patient compliance was unknown,
the majority were acquired in Africa (n = 35): 24 in West Africa, seven in East Africa, one in Central Africa, one in
Southern Africa,§ and two in an unspecified African region. Two cases were acquired outside Africa: one in the Caribbean (Haiti)
and one in South America (Brazil). Serum drug levels were not available for any of these 37 patients.
Eight of the 16 P. malariae cases among those who reported taking a recommended antimalarial drug were acquired
in Africa. In three (18.8%) of these 16 cases, noncompliance with antimalarials was reported. In the 13 remaining cases,
whether the patient complied with prophylaxis was unknown; four had traveled in the Americas, five in Africa, three in Asia, and
one in Oceania.
Purpose of Travel
Purpose of travel to malaria-endemic areas was reported for 635 (77.0%) of the 825 U.S. civilians with imported
malaria (Table 6). Of the U.S. civilians with malaria, the largest percentage (35.9%) were persons who had visited friends or
relatives in malarious areas; the second and third largest percentages, 10.3% and 10.2%, had traveled for tourism and to do
missionary work, respectively.
Malaria During Pregnancy
A total of 35 cases of malaria were reported among pregnant women in 2000, representing 7.8% of cases among
women. Fifteen (42.9%) were among U.S. civilians. Eleven of these 15 women (73.3%) had traveled to visit friends and relatives,
of whom 72.7% traveled in Africa. Only 1 pregnant woman (6.9%) reported taking prophylaxis, compared with 31.1%
of nonpregnant women. Twelve women (86.7%) were hospitalized, compared with 56.3% of nonpregnant women.
Malaria Acquired in the United States
Congenital Malaria
Two cases of congenital malaria were reported in 2000 and are described in the following case reports:
Case 1. On September 7, 2000, a previously healthy 10-week-old female infant residing in North Carolina
experienced fever and dark urine (10). Examination revealed a temperature of 103.7ºF but no other abnormal findings.
Laboratory studies included an elevated white blood cell count (24,600/µL) and low hemoglobin (8.7 g/dL). She was admitted to
a local hospital to rule out sepsis, and intravenous therapy with ampicillin and cefotaxime was begun. On September
8, blood films for malaria were obtained and were reported the next day to contain
P. malariae. Treatment with chloroquine was initiated. Bacterial cultures of urine, blood, and cerebrospinal fluid obtained at admission indicated no growth.
The child's clinical status improved, and she was discharged on
September 13, having completed chloroquine treatment in
the hospital.
The mother reported that her pregnancy had been uncomplicated, and the neonate had been born by cesarean
delivery because of failure to progress during labor. The infant had not traveled outside her home city or received any
blood products. Both parents had emigrated from the Democratic Republic of the Congo (formerly Zaire), the father 5
years previously and the mother 4 years previously. The mother reported being treated for malaria with a full course
of chloroquine before leaving the Congo in 1996. Both parents reported no episodes of malaria, febrile illness, foreign
travel, or blood transfusion after arriving in the United States.
Pretreatment malaria testing of the mother with thick and thin blood films prepared at four different times did
not indicate malaria parasites (drawn September 10, 12, 13, and 21). Subsequent serologic testing revealed
positive immunoglobulin G (IgG) titers against P.
falciparum and P. malariae (both 1:16,384), and against
P. vivax and P. ovale (both 1:1,024), indicating previous infection with malaria. Polymerase chain reaction (PCR) analysis on
blood collected on September 22 was negative for
Plasmodium species. However, she was presumptively treated
with chloroquine.
Case 2. In November 2000, a male infant, aged 1 month, was admitted to a Georgia hospital because of poor oral
intake and pallor. On examination, the baby was irritable and pale, with a heart rate of 95 beats/minute and
mild
hepatosplenomegaly. Laboratory examination revealed a hemoglobin of 2.5 g/dL, and a malaria blood film indicated
P. vivax. The infant was treated with oral chloroquine and recovered without complications.
The infant was born by normal spontaneous vaginal delivery to a Guatemalan mother, who reported a history of
malaria in Guatemala in November 1999, for which she was treated with proguanil. She immigrated to the United States
in March 2000, where she continued to do well until April. At that time, she reportedly experienced fever and chills
and self-medicated with an unknown oral medication. The mother's thick and thin blood smears were negative, as was
PCR. Immunofluorescent assay titers performed on the mother's serology were 1:256 to
P. vivax, 1:64 to P. falciparum, 1:64
to P. malariae, and 1:64 to P. ovale, indicating prior infection with malaria.
Induced Malaria
Two cases of induced malaria were reported in 2000 and are described in the following case reports:
Case 1. On August 4, 2000, a female nurse aged 55 years, sustained a needle-stick injury while caring for a patient in
a Massachusetts hospital emergency department. The patient had returned recently from Cote d'Ivoire and had a
fever. Infection with P. falciparum was diagnosed, and the patient responded well to treatment with quinine and doxycycline.
On September 11, the nurse experienced fever, chills, and vomiting. Infection with
P. falciparum was diagnosed, and the nurse was admitted to the hospital and treated successfully with quinine and doxycycline. She reported no travel
to malaria-endemic areas nor transfusion of blood products.
Case 2. On September 23, 2000, a man aged 71 years who had a history of hypertension, hypercholesterolemia,
diabetes mellitus, and endocarditis was admitted to a Massachusetts hospital because of progressive weakness, nausea,
and vomiting. Acalculous cholecystitis was diagnosed. Review of the complete blood count was suspicious for
Babesia. The patient was administered a single dose of intravenous doxycycline and started on intravenous clindamycin at a dosage
of 600 mg every 8 hours. Blood films sent to CDC revealed
P. falciparum. Therapy was changed to quinine and
doxycycline and the patient improved.
The patient reported no recent travel, having been house-bound for the previous 4--5 months because of his
chronic illnesses. He had received 1 unit of packed red blood cells (PRBC) on July 7 and 13; he had also received 1 unit of
PRBC, 6 units of platelets, and 6 units of fresh frozen plasma during coronary artery bypass graft and mitral valve repair
on August 8, and 1 unit of PRBC for gastrointestinal bleeding on September 8. Five of the six platelet donors and all
four PRBC donors were traced, and their blood films, PCR, and serology did not indicate malaria. One donor refused
to cooperate with the trace-back investigation.
Investigation revealed that a nurse, who had cared for this patient during his emergency room visit on September 8,
had previously experienced P. falciparum malaria (see case 1 in this section). The nurse's exposure was thought to be from
a needle-stick injury sustained at another local hospital on August 4. At that time, she had been caring for a patient
who was diagnosed with P. falciparum after a trip to Cote d'Ivoire.
PCR analysis demonstrated that the parasite identified in induced cases 1 and 2 are clonal (i.e., related). These
results strongly imply that malaria was transmitted
between the two persons. Technical difficulties with
specimens from the Cote d'Ivoire patient prohibited PCR analysis to determine clonal identity.
Deaths Attributed to Malaria
Six deaths attributable to malaria were reported during 2000 and are described in the following case reports:
Case 1. On January 16, 2000, a female aged 91 years who was a resident of a long-term care facility in California
was evaluated by her physician and determined to have microcytic anemia (hemoglobin 8.3 g/dL), thrombocytopenia
(platelet count: 53,000/µL), and renal insufficiency (blood urea nitrogen: 39 mg/dL and creatinine: 1.4 mg/dL). A blood
film indicated P. malariae, and she was treated with chloroquine. Years had passed since she had traveled to a malarious
area (China). Her course was complicated by pneumonia, and she died on January 26.
Case 2. On May 5, 2000, a female aged 47 years and a resident of Kenya arrived in California to visit family. She visited
a physician on May 16 with complaints of nausea and abdominal pain; a urinary tract infection was diagnosed, and she
was treated with nitrofurantoin. She was examined at a California hospital the following day; she was jaundiced, and
hepatitis was diagnosed. She refused hospitalization and insisted on continuing her travels to Canada on May 18. She required
a wheelchair for transport in the airport but was able to walk onto the airplane. While on the airplane she felt ill,
vomited,
and collapsed in the airplane's bathroom. The airplane was diverted to an airport in Nevada, and she was transported
to an emergency department where she was found to be comatose and in acute respiratory failure. Her
laboratory examinations revealed P.
falciparum malaria (9.3% parasitemia) as well as metabolic acidosis, thrombocytopenia
(platelet count: 13,000/µL), and abnormal liver function (aspartate aminotransferase: 117 U/L; alanine aminotransferase:
71U/L; total bilirubin: 8.2 mg/dL). Computerized tomography of the head indicated probable cerebral edema. Therapy
with intravenous quinidine gluconate was begun. Her condition deteriorated, necessitating assisted ventilation. Her course
was further complicated by supraventricular tachycardia and later bradycardia and
hypotension unresponsive to therapy with intravenous fluids and vasopressors, and she died in the emergency department. Blood cultures, taken on arrival at
the hospital, later grew both Staphylococcus
aureus and coagulase-negative staphylococcus.
Case 3. On November 7, 2000, a woman aged 24 years was examined in the emergency department of a
Vermont hospital and was prescribed antibiotics. She was not admitted to the hospital and was found deceased 4 days later.
She had recently been on a 3-month trip to Ghana, and she had begun experiencing symptoms within days after returning
to the United States. She did not take prophylaxis during her travel in Africa. Her blood films revealed
P. falciparum, and the state medical examiner reported the cause of death as cerebral malaria secondary to
P. falciparum.
Case 4. On September 22, 2000, a Senegalese man aged 39 years who reported a history of congestive heart
failure (CHF), peptic ulcer disease, and hepatitis, was treated at a Georgia hospital. The patient had arrived in the United
States approximately 2 months earlier to visit friends. On examination, he was diaphoretic, but without fever, and in
moderate respiratory distress; he also had signs and symptoms consistent with CHF. The patient was admitted with a diagnosis
of CHF and was treated with intravenous diuretics and inotropic agents. After admission, he became nauseated and
febrile. Laboratory studies demonstrated abnormal liver function, although viral hepatitis serology tests were
negative. Plasmodium parasites were identified on a malaria blood film (September 24), and treatment with quinine
and doxycycline was begun. The species was subsequently identified as nonfalciparum malaria, and the treatment was
changed to chloroquine. On September 26, the patient was lethargic with altered mental status, and he was transferred to
the medical intensive care unit. On September 27, the patient suffered a cardiac arrest and was unable to be
resuscitated. Species confirmation of blood films, taken during his admission, occurred postmortem and revealed
P. ovale.
Case 5. On April 3, 2000, a man aged 55 years with multiple medical problems was examined at an
emergency department of a Florida hospital. He complained of generalized weakness, cough, and fever, and on examination, he
was hypotensive and febrile (105ºF). Malaria was
diagnosed (species undetermined), and the patient was admitted to
the intensive care unit. He was initially treated with oral chloroquine and then oral quinine sulfate.
His medical history included atrial fibrillation, sleep
apnea, liver disease, and morbid obesity. The patient had
been noncompliant with his regular medications before hospitalization. Moreover, the patient, a U.S. civilian, had
recently traveled to Mexico, Nicaragua, Honduras, and Ecuador, and he had not taken any prophylaxis during this 6-week
trip. He returned to the United States on March 30, a total of 4 days before admission to the hospital. His course
was complicated by pulmonary embolism, cardiac arrhythmia (supraventricular tachycardia and atrial fibrillation),
congestive cardiac failure, disseminated intravascular coagulation, renal failure, retroperitoneal bleeding, and
malignant hyperthermia. He received multiple transfusions of blood products. On April 20, as he was being prepared for insertion
of an inferior vena cava filter, he suffered a cardiac arrest and died. Species confirmation of blood films taken during
his admission occurred postmortem and demonstrated
P. falciparum.
Case 6. On December 17, 2000, a male sailor from West Africa, aged 37 years, was admitted to a Florida hospital after
a fall onboard his ship. He complained of generalized weakness, cough, and loss of appetite during the previous weeks.
He had recently traveled from Liberia through Ghana and the Cape Verde Islands and arrived in Baltimore, Maryland,
on December 12. While in Baltimore, he was seen by a physician and was prescribed erythromycin for his symptoms. He
had not been taking any prophylaxis for malaria.
On examination, he was febrile (101.6ºF), tachycardic (138 beats/minute) and jaundiced. His laboratory test
results revealed a normal white blood cell count
(8,100/µL), thrombocytopenia (platelets: 68,000/µL), and anemia
(hemoglobin: 12.2 g/dL). He was admitted with a diagnosis of malaria
(P. falciparum) and acute renal failure, and treated with
quinine and doxycycline. His hospital course was further complicated by respiratory failure and gastrointestinal (GI) bleeding.
He was placed on assisted ventilation, and he received multiple blood transfusions for anemia secondary to malaria and
GI bleeding. Subsequent malaria blood films, on December 20 and 21, did not indicate malaria parasites. However,
the
patient's condition continued to deteriorate and he
experienced multiorgan failure. Despite supportive therapy,
the patient died on January 5, 2001.
Discussion
A total of 1,402 cases of malaria were reported to CDC for 2000, representing a 9.0% decrease from the 1,540
cases reported for 1999. This change primarily resulted from a decrease in cases acquired in Africa and the Americas. Beginning
in 2000, CDC routinely contacts state health departments to ask for outstanding reports from the previous reporting year or
for a statement that reporting is complete. The decrease in cases in 2000, compared with 1999, possibly is a result of
expected variation in the reporting system, although other possibilities include decreased international travel, changing patterns
of travel (e.g., immigration from malarious areas or adventure tourism), or an increased use of effective
antimalarial chemoprophylaxis.
One reason for conducting malaria surveillance is to monitor for prophylaxis failures that might indicate emergence of
drug resistance; however, >70% of imported malaria among U.S. civilians occurred among persons who were either not
taking prophylaxis or were taking nonrecommended prophylaxis for the region to which they were traveling. Among the 117
cases where appropriate prophylaxis was reported, 60 (i.e., 37
P. falciparum, 10 P. vivax, and 13
P. malariae) had insufficient information to determine whether these represented problems with adherence while using correct
antimalarial chemoprophylaxis or emerging drug resistance. No conclusive evidence existed to indicate a single national or regional
source of infection among this group of patients or the failure of a particular chemoprophylactic regimen. Health-care providers
are encouraged to contact CDC rapidly whenever they suspect chemoprophylaxis failure, thus enabling measurement of serum
drug levels of the antimalarial drugs in question.
In 2001, to be better able to evaluate chemoprophylaxis failures, CDC revised the NMSS case report form to
facilitate collection of more thorough data regarding chemoprophylaxis. The current form solicits more detailed information
regarding the prescribed regimen, the degree of compliance with the regimen, and the reasons for noncompliance, if any. Data
gathered from the responses will be useful in generating public health messages to improve use of antimalarial chemoprophylaxis,
and therefore decrease malaria-associated morbidity and mortality among U.S.
civilians.
The importance of taking correct precautions and chemoprophylaxis is underscored by the six fatal cases of malaria
that occurred in the United States in 2000. An earlier review of deaths attributed to malaria in the United States identified
certain risk factors for fatal malaria, including failure to take recommended antimalarial chemoprophylaxis, refusal of or delay
in seeking medical care, and misdiagnosis
(11).
The occurrence of 15 cases of malaria among pregnant U.S. civilians is cause for concern also. Malaria during
pregnancy among nonimmune women is more likely to result in severe disease or contribute to an adverse outcome for the woman
than malaria in a nonpregnant woman (12); the fetus might be adversely affected as well
(13). Pregnant travelers should be counseled to avoid travel to malarious areas, if possible. If deferral of travel is impossible, pregnant women should
be informed that the risks for malaria outweigh those associated with prophylaxis and that safe chemoprophylaxis regimens
are available. Specific guidance for pregnant travelers is available from CDC's website at
http://www.cdc.gov/travel/mal_preg_pub.htm.
Signs and symptoms of malaria are often nonspecific, but fever is usually present. Other symptoms include headache,
chills, increased sweating, back pain, myalgia, diarrhea, nausea, vomiting, and cough. Prompt diagnosis requires that malaria
be included in the differential diagnosis of illness in a febrile person with a history of travel to a malarious area. Clinicians
should ask all febrile patients for a travel history, including when evaluating febrile illnesses among international visitors,
immigrants, refugees, migrant laborers, and international travelers.
Treatment for malaria should be initiated immediately after the diagnosis has been confirmed by a positive blood
film. Treatment should be determined on the basis of the infecting
Plasmodium species, the probable geographic origin of
the parasite, the parasite density, and the patient's clinical status
(14). Although nonfalciparum malaria rarely
causes complications, persons with P.
falciparum infection are at risk for developing life-threatening complications.
Health-care workers should be familiar with prevention, recognition, and treatment of malaria and are encouraged
to consult appropriate sources (Table 7) for malaria treatment recommendations or call CDC's National Center for
Infectious Diseases, Division of Parasitic Diseases at 770-488-7788. Detailed recommendations for preventing malaria are available
24
hours/day from CDC by telephone at 877-394-8747 (toll-free voice information system) or 888-232-3299 (toll-free
facsimile request line), or on the Internet at http://www.cdc.gov/travel/diseases.htm#malaria. In addition, CDC biannually
publishes recommendations in the Health Information for International Travel
(9), which is available for purchase from the
Public Health Foundation at 877-252-1200 or 301-645-7773; it is also available and updated more frequently on CDC's
Internet site at http://www.cdc.gov/travel.
CDC provides support for the diagnosis of malaria through DPDx, a program that enhances diagnosis of parasitic
diseases throughout the world. It includes an Internet site, http://www.dpd.cdc.gov/dpdx, that contains information
regarding laboratory diagnosis, geographic distribution, clinical features, treatment, and life cycles of >100 parasite species. The
DPDx Internet site is also a portal for diagnostic assistance for health-care providers through telediagnosis. Digital images
captured from diagnostic specimens are submitted for diagnostic consultation through electronic mail. Because laboratories
can transmit images to CDC and rapidly obtain answers to their inquiries, this system allows more efficient diagnosis of
difficult cases and more rapid dissemination of information. Approximately 36 laboratories in 34 states have or are in the process
of acquiring the hardware to perform telediagnosis.
Acknowledgments
The authors acknowledge the state, territorial, and local health departments, health-care providers, and laboratories for reporting
this information to CDC.
References
World Health Organization. World malaria situation in 1994. Wkly Epidemiol Rec 1997;72:269--76.
Bremen JG. Ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. Am J Trop Med Hyg 2001;64(S1):1--11.
Pan American Health Organization. Report for registration of malaria eradication from United States of America. Washington, DC: Pan
American Health Organization, 1969.
Zucker JR. Changing patterns of autochthonous malaria transmission in the United States: a review of recent outbreaks. Emerg Infect
Dis 1996;2:37--43.
Lackritz EM, Lobel HO, Howell J, Bloland P, Campbell CC. Imported
Plasmodium falciparum malaria in American travelers to
Africa: implications for prevention strategies. JAMA 1991;265:383--5.
Stroup DF. Special analytic issues. In: Teutsch SM, Churchill RE, ed. Principles and practice of public health surveillance. New York, NY:
Oxford University Press, 1994;143--5.
World Health Organization. Terminology of malaria and of malaria eradication: report of a drafting committee. Geneva, Switzerland: World
Health Organization, 1963;32.
CDC. Health information for international travel, 2001--2002. Atlanta, GA: US Department of Health and Human Services, Public
Health Service, CDC, National Center for Infectious Diseases, 2001.
Greenberg AE, Lobel HO. Mortality from
Plasmodium falciparum malaria in travelers from the United States, 1959 to 1987. Ann Intern
Med 1990;113:326--7.
Luxemburger C, Ricci F, Nosten F, Raimond D, Bathet S, White NJ. Epidemiology of severe malaria in an area of low transmission in
Thailand. Trans R Soc Trop Med Hyg 1997;91:256--62.
Nosten F, ter Kuile F, Maelankirri L, Decludt B, White NJ. Malaria during pregnancy in an area of unstable endemicity. Trans R Soc Trop Med
Hyg 1991;85:424--9.
Zucker JR, Campbell CC. Malaria: principles of prevention and treatment. Infect Dis Clin North Am 1993;7:547--67.
* To obtain confirmation diagnosis of blood films from questionable cases and to obtain appropriate treatment recommendations, contact either your
state or local health department or CDC's National Center for Infectious Diseases, Division of Parasitic Diseases, Malaria Epidemiology Branch at
770-488-7788.
†East, West, and Central
Africa: Angola, Benin, Burkina Faso, Burundi, Cameroon, Cape Verde Islands, Central African Republic, Chad,
Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Djibouti, Equatorial Guinea, Eritrea, Ethiopia, Gabon, The Gambia, Ghana, Guinea,
Guinea-Bissau, Kenya, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Niger, Nigeria, Réunion, Rwanda, São Tomé and
Príncipe, Senegal, Seychelles, Sierra Leone, Somalia, Sudan, Togo, Uganda, Tanzania, Zambia, and Zimbabwe.
§Southern Africa: Botswana, Lesotho, Namibia, Saint Helena, South Africa, and Swaziland.
* In Figures A-1 and A-2, the hands are illustrated ungloved to better indicate their placement during the procedures. However, wearing gloves
while processing blood specimens is recommended to prevent transmission of bloodborne pathogens
(MMWR 1988;37:377--82, 387--8 and MMWR 1987;36[No.
S2]).
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites. URL addresses listed in MMWR were current as of
the date of publication.
All MMWR HTML versions of articles are electronic conversions from ASCII text
into HTML. This conversion may have resulted in character translation or format errors in the HTML version.
Users should not rely on this HTML document, but are referred to the electronic PDF version and/or
the original MMWR paper copy for the official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents,
U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800.
Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to
mmwrq@cdc.gov.
